Microvascular Obstruction Identifies a Subgroup of Patients Who Benefit from Stem Cell Therapy Following ST-Elevation Myocardial Infarction.

[1]  T. Henry,et al.  Increasing Myocardial Edema Is Associated With Greater Microvascular Obstruction In ST-Segment Elevation Myocardial Infarction. , 2022, American journal of physiology. Heart and circulatory physiology.

[2]  L. Stanberry,et al.  Circadian dependence of microvascular obstruction during ST-segment elevation myocardial infarction. , 2022, International journal of cardiology.

[3]  I. Porto,et al.  Index of Microcirculatory Resistance as a Tool to Characterize Microvascular Obstruction and to Predict Infarct Size Regression in Patients With STEMI Undergoing Primary PCI. , 2019, JACC. Cardiovascular imaging.

[4]  E. Ohman,et al.  Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials , 2017, European heart journal.

[5]  Doris A Taylor,et al.  TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function Final 2-Year Analysis , 2017, Circulation research.

[6]  J. Trochu,et al.  Predictors of ventricular remodelling in patients with reperfused acute myocardial infarction and left ventricular dysfunction candidates for bone marrow cell therapy: insights from the BONAMI trial , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  W. Rottbauer,et al.  Impact of cell number and microvascular obstruction in patients with bone-marrow derived cell therapy: final results from the randomized, double-blind, placebo controlled intracoronary Stem Cell therapy in patients with Acute Myocardial Infarction (SCAMI) trial , 2013, Clinical Research in Cardiology.

[8]  M. Sever,et al.  Effects of Intracoronary CD34+ Stem Cell Transplantation in Nonischemic Dilated Cardiomyopathy Patients: 5-Year Follow-Up , 2013, Circulation research.

[9]  Doris A Taylor,et al.  Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. , 2012, JAMA.

[10]  A. Witkowski,et al.  The size does not matter - the presence of microvascular obstruction but not its extent corresponds to larger infarct size in reperfused STEMI. , 2012, European journal of radiology.

[11]  M. Schocke,et al.  Prognostic value at 5 years of microvascular obstruction after acute myocardial infarction assessed by cardiovascular magnetic resonance , 2012, Journal of Cardiovascular Magnetic Resonance.

[12]  M. Schocke,et al.  Patterns of myocardial perfusion in the acute and chronic stage after myocardial infarction: a cardiac magnetic resonance study. , 2012, European journal of radiology.

[13]  Doris A Taylor,et al.  Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. , 2011, JAMA.

[14]  B. Klein,et al.  Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. , 2011, European heart journal.

[15]  T. Henry,et al.  Results of a phase 1, randomized, double-blind, placebo-controlled trial of bone marrow mononuclear stem cell administration in patients following ST-elevation myocardial infarction. , 2010, American heart journal.

[16]  R. Virmani,et al.  Microvascular obstruction: underlying pathophysiology and clinical diagnosis. , 2010, Journal of the American College of Cardiology.

[17]  P. Algra,et al.  Assessment of microvascular obstruction and prediction of short-term remodeling after acute myocardial infarction: cardiac MR imaging study. , 2009, Radiology.

[18]  Stephen J Riederer,et al.  Dynamic Tracking During Intracoronary Injection of 18F-FDG-Labeled Progenitor Cell Therapy for Acute Myocardial Infarction , 2007, Journal of Nuclear Medicine.

[19]  A. Zeiher,et al.  Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. , 2006, The New England journal of medicine.

[20]  Dong Soo Lee,et al.  Tissue distribution of 18F-FDG-labeled peripheral hematopoietic stem cells after intracoronary administration in patients with myocardial infarction. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  S. Dymarkowski,et al.  Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial , 2006, The Lancet.

[22]  A. Kitabatake,et al.  Lack of Myocardial Perfusion Immediately After Successful Thrombolysis: A Predictor of Poor Recovery of Left Ventricular Function in Anterior Myocardial Infarction , 1992, Circulation.

[23]  S. Fisher,et al.  Stem cell treatment for acute myocardial infarction. , 2012, The Cochrane database of systematic reviews.